List of Field Safety Notices from 23 to 27 June 2025.
Similar Posts
Find product information about medicines
How to get information including patient information leaflets (PILs), details on how the medicine can be used (SmPCs) and scientific reports (PARs).
Class 3 Medicines Recall: Kimmtrak 200 micrograms/mL concentrate for solution for infusion, Immunocore Limited, EL(25)A/28
Immunocore Limited is recalling the batches listed below as a precautionary measure. The recall is due to a decrease in potency identified during stability testing. All other stability test results remain within specification.
IXCHIQ Chikungunya vaccine: temporary suspension in people aged 65 years or older
The Commission on Human Medicines (CHM) has temporarily restricted use of the IXCHIQ Chikungunya vaccine in people aged 65 years and over following very rare fatal reactions reported globally. This is a precautionary measure while the MHRA conducts a safety review. The IXCHIQ vaccine will be available on the UK market from 18 June 2025.
Decentralised manufacture: Clinical Trial Authorisation (CTA) and Good Clinical Practice (GCP)
Guidance for clinical trials that use Decentralised Manufactured Investigational Medicinal Products (IMPs).
UK and Singapore launch a regulatory innovation corridor to speed up access to breakthrough health technologies
Patients in the UK and Singapore could gain faster access to cutting-edge healthcare innovations under a new partnership bringing two globally respected regulators together with one of the world’s leading biotech creators.
Types of application for marketing authorisations (legal basis of applications)
You must include the appropriate legal basis for your application when you apply to MHRA for a marketing authorisation.